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Abstract
Anion channels perform a diverse range of functions and have been implicated in ATP release,
volume regulation, and phosphatidylserine exposure. Platelets have been shown to express
several anion channels but their function is incompletely understood. Due to a paucity of
specific pharmacological blockers, we investigated the effect of extracellular chloride substitu-
tion on platelet activation using aggregometry and flow cytometry. In the absence of extra-
cellular chloride, we observed a modest reduction of the maximum aggregation response to
thrombin or collagen-related peptide. However, the rate of aggregation was substantially
reduced in a manner that was dependent on the extracellular chloride concentration and
aggregation in the absence of chloride was noticeably biphasic, indicative of impaired second-
ary signaling. This was further investigated by targeting secondary agonists with aspirin and
apyrase or by blockade of the ADP receptor P2Y12. Under these conditions, the rates of
aggregation were comparable to those recorded in the absence of extracellular chloride.
Finally, we assessed platelet granule release by flow cytometry and report a chloride-depen-
dent element of alpha, but not dense, granule secretion. Taken together these data support a
role for anion channels in the efficient induction of platelet activation, likely via enhancement
of secondary signaling pathways.
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Introduction
In contrast to the role of cations (i.e., Ca2+, K+, and Zn2+) [1–3],
the contribution(s) of anions to platelet activation remains
unclear. Anion channels perform diverse functions including reg-
ulatory volume decrease [4], phosphatidylserine exposure [5], and
ATP release [6]. Early patch clamp recordings demonstrated
functional expression of Ca2+-activated Cl− channels in platelets
[7, 8] and a megakaryocyte-like DAMI cell line [9]. Proteomic
[10] and transcriptomic [11] analyses have since identified numer-
ous anion channels that may be expressed by platelets. Of these,
functional expressions of CLIC1 (Intracellular Cl− channel-1)
[12], TMEM16F [13], and pannexin-1 [14] have been confirmed.
Indicative of a hemostatic role for anion channels, CLIC1- and
TMEM16F-deficient mice have associated platelet-related bleed-
ing phenotypes [12, 13]. Additionally, pannexin-1 channels have
been shown to amplify platelet activation responses to threshold
agonist concentrations [14]. These ATP-permeable channels are
associated with inflammatory conditions and may contribute to
atherosclerosis [15].
Given the lack of specific anion channel blockers, we focus on
the effect of extracellular Cl− ([Cl−]o) substitution on platelet
activation. Our experiments highlight a role for anion channels
in modulating the rate of platelet aggregation.
Methods
Materials
Aspirin, apyrase, and thrombin were from Sigma (Poole, UK). AR-
C66096 was from Tocris Bioscience (Bristol, UK). Cross-linked
collagen-related peptide (CRP-XL) was prepared as described pre-
viously [16] and supplied by R. Farndale (Cambridge, UK). Unless
indicated, all other reagents were from Sigma.
Washed platelet preparation
This study was approved by the local Ethics Committee at Anglia
Ruskin University. Human blood was collected from healthy
volunteers following informed consent in accordance with the
Declaration of Helsinki. Blood was collected into 11 mM sodium
citrate and washed platelets were prepared as described pre-
viously [17]. Platelets were resuspended in a nominally calcium-
free buffer containing (in mM) 145 NaCl, 5 KCl, 1 MgCl2, 10
glucose, 10 HEPES, titrated to pH 7.35 with NaOH. Where
indicated, [Cl−]o was substituted by equimolar gluconate.
Aggregometry
Platelet aggregation was monitored as described previously
using an AggRam aggregometer (Helena Biosciences,
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Gateshead, UK) [17]. In the experiments of Figure 1c, aliquots
of 151 and 1 mM [Cl−]o-containing platelet suspensions were
mixed 5 min prior to agonist addition. Platelets were preincu-
bated with each drug(s) for 5 min at 37°C.
Granule release
Thrombin-evoked alpha and dense granule release was
assessed by flow cytometry using fluorescently conjugated
CD62P and CD63 antibodies (BD Biosciences, Oxford, UK),
Figure 1. Extracellular chloride is required for
efficient platelet activation. (a) Washed platelets
were stimulated by increasing concentrations of
thrombin or 1 µg mL−1 CRP-XL in the presence
of 151 mM (black) or 1 mM (gray) [Cl−]o.
Representative aggregation traces are shown for
each condition (ai). Maximum aggregation (aii)
and the initial rate of aggregation (aiii) were
calculated for each condition. (b) In the presence
of 2 mM [Ca2+]o, [Cl
−]o substitution continued
to reduce the initial rate of thrombin-evoked
aggregation. (c) The sensitivity of thrombin-
evoked (0.1 U mL−1) aggregation to Cl− was
assessed by increasing [Cl−]o from 1 to 151 mM
in 30 mM increments. Representative traces (ci),
maximum (cii) and initial rate of thrombin-
induced (0.1 U mL−1) aggregation (ciii) for each
[Cl−]o are shown. The rate of aggregation
increased across the concentration range with an
EC50 = 46.5 ± 23.3 mM. Data are representative
of a minimum of four independent experiments.
Thrombin and CRP-XL data sets were analyzed
by two-way ANOVA and Student’s t test,
respectively.
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respectively. Antibody binding was monitored for 5 min using
an Accuri C6 Flow cytometer (BD Biosciences) and the per-
centage of positive cells was calculated within FlowJo (V10.2,
Oregon, USA).
Data analysis and statistics
Maximum aggregation (%) and the initial rate of aggregation (% s−1)
were calculated in Excel (Microsoft, Redmond, Washington, USA),
where rate was determined as the change in aggregation (%) in the
first 30 s following shape change. Data were analyzed in GraphPad
Prism by two-way ANOVA or Student’s t test as indicated and are
representative of a minimum of four independent experiments. ***,
**, *, and ns denote P < 0.001, P < 0.01, P < 0.05, and not
significant, respectively.
Results
Platelet aggregation was assessed in the presence/absence of [Cl−]o
in response to increasing thrombin concentrations (Figure 1a).
Removal of [Cl−]o did not affect the maximum aggregation
recorded across a 5-min time course in response to 0.03, 0.3, or
1 U mL−1 thrombin (Figure 1aii). A reduction from 82.3 ± 1.9% to
62.2 ± 6.0% (P < 0.001, Figure 1aii) was observed at an
Figure 2. Role for secondary signaling during
Cl–-dependent platelet aggregation. (a) Washed
platelets were preincubated with 100 µM aspirin
(cyclooxygenase inhibitor) and 5 U mL−1 apyr-
ase (ectonucleotidase) prior to performing
aggregometry in the presence of 151 mM
(black) or 1 mM (gray) [Cl−]o. Representative
traces (ai), maximum (aii), and initial rate (aiii)
of thrombin-induced (0.1 U mL−1) aggregation
are shown in the presence of vehicle control
(0.1% ethanol) or aspirin plus apyrase. (b)
Summary data for maximum (bi) and initial rate
of thrombin-evoked (0.1 U mL−1) platelet
aggregation (bii) in the presence of vehicle
control (H2O) or 1 µM Ar-C66096 (P2Y12
inhibitor). (c) Alpha (i) and dense (ii) granule
release before (unstimulated) and after 0.1 U
mL−1 thrombin stimulation was assessed by
flow cytometry using fluorescently labeled
CD62P and CD63 antibodies, respectively. Data
are representative of a minimum of four inde-
pendent experiments and data were analyzed by
two-way ANOVA.
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intermediate concentration (0.1 U mL−1). Cl− substitution affected
the kinetics of platelet activation as the aggregation rate decreased
by 1.1 ± 0.2%, 1.1 ± 0.2%, and 1.0 ± 0.2% s−1 in response to
stimulation by 0.1, 0.3, and 1 U mL−1 thrombin, respectively
(P < 0.01, Figure 1aiii). Similar effects were observed in the
presence of 2 mM Ca2+ (Figure 1b), suggesting that this effect
was not due to Ca2+ buffering. This observation was not exclusive
to thrombin-evoked aggregation; removal of [Cl−]o reduced max-
imal CRP-XL-induced (1 µg mL−1) aggregation by 23.5 ± 3.9%
(P < 0.01, Figure 1aii) and the rate decreased by 1.2 ± 0.1% s−1
(P < 0.001, Figure 1aiii). The sensitivity of thrombin-evoked
(0.1 U mL−1) aggregation to Cl− was assessed by increasing
[Cl−]o from 1 to 151 mM (30 mM increments; Figure 1c). There
was no change in maximum aggregation beyond 31 mM [Cl−]o yet
rates increased across the concentration range
(EC50 = 46.5 ± 23.3 mM).
Differences in aggregation rate may be due to reduced second-
ary signaling in the absence of [Cl−]o. Platelets were preincubated
with 100 µM aspirin and 5U mL−1 apyrase to assess contributions
by thromboxane A2 and extracellular nucleotides. These com-
pounds reduced maximum aggregation in response to 0.1 U
mL−1 thrombin by 56.6 ± 10.2% (P < 0.001) and 31.6 ± 10.2%
(P < 0.05, Figure 2ai, ii) in the presence of 151 and 1 mM [Cl−]o,
respectively. The rate of platelet aggregation following aspirin and
apyrase treatment in the presence of 151 mM (0.6 ± 0.2% s−1) or
1 mM (0.38 ± 0.08% s−1) [Cl−]o was comparable to that of 1 mM
[Cl−]o control (0.7 ± 0.1% s
−1; P > 0.05, Figure 2aiii).
P2Y12-mediated signaling is a major step during integrin
αIIbβ3 activation [18, 19] and reduced ADP availability may
account for the observed aggregation defect. 0.1 U mL−1 throm-
bin-evoked aggregation in the presence of a P2Y12 inhibitor (1
µM AR-C66096) decreased by 36.7 ± 8.2% and 51.2 ± 7.4% in
the presence of 151 and 1 mM [Cl−]o (P < 0.01, Figure 2bi),
respectively. It is noteworthy that no differences between the
aggregation rate of AR-C66096-treated platelets in 151 or 1 mM
[Cl−]o and the 1 mM [Cl
−]o control were observed (P > 0.05,
Figure 2bii), suggesting a role for P2Y12 during Cl–-dependent
aggregation. Finally, we assessed thrombin-induced granule
release by flow cytometry. Peak alpha granule release was
reduced from 72.4 ± 2.9% to 59.9 ± 1.6% (P < 0.001,
Figure 2c), while dense granule release was unaffected by Cl−
substitution (P > 0.05, Figure 2c).
Conclusions
Here we demonstrate that [Cl−]o enhances the rate of platelet
aggregation in a concentration-dependent manner (Figure 1).
This effect was equivalent to blockade of secondary mediators
and P2Y12 inhibition (Figure 2). One possible explanation of
these data is that [Cl−]o is required for efficient release of ATP
and/or ADP from the platelet, but we failed to observe a change in
dense granule secretion (Figure 2c). Pannexin-1 has been shown
to activate in response to elevation of intracellular Ca2+ ([Ca2+]i)
[20], facilitating cytosolic ATP release [14]. It has been suggested
that ADP release may occur via a similar mechanism [21]. Given
that release of alpha granule cargo (e.g., fibrinogen, thrombin, and
Zn2+) is required for aggregation and is enhanced by P2Y12
signaling [22–24], it is possible that [Cl−]o enhances platelet
activation by mediating efficient alpha granule secretion.
Reduction of [Cl−]o has been shown to substantially reduce
thrombin-plus-CRP-XL-mediated elevation of [Ca2+]i in a similar
manner to that of Cl− channel blockers [25]. It has been suggested
that Cl− currents hyperpolarize the cell, increasing driving force
for Ca2+ influx [9]. However, the platelet Cl− equilibrium is ≈35
mV in the platelet [7], meaning activation of a Cl− conductance
would depolarize rather than hyperpolarize platelets. Reduced
Ca2+ influx may be due to reduced secondary signaling, rather
than altered membrane potential.
We have focused on the contribution of [Cl−]o by way of ionic
substitution experiments because of the paucity of specific pharma-
cological tools to study anion channels. This may also explain why
anion channels have previously received much less attention than
cation channels. It is worth noting that anion channels have been
associated with cystic fibrosis, bleeding phenotypes, and inflamma-
tory conditions [12, 13, 15, 26, 27] and may represent valuable
therapeutic targets, as demonstrated by clinical use of CFTR mod-
ulators [28]. Further work will be required to investigate the contribu-
tion(s) by the cohort of platelet anion channels during platelet
activation.
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